Literature DB >> 30539236

Impact of Patient and Lesion Characteristics on Drug-Coated Balloon Angioplasty in the Femoropopliteal Artery: A Pooled Analysis of Four Randomized Controlled Multicenter Trials.

Thomas Albrecht1,2, Antonia Ukrow3, Michael Werk4, Gunnar Tepe5, Thomas Zeller6, Dirk-Roelfs Meyer7, Maren Kutschera8, Ulrich Speck8, Matthias Waliszewski9,10.   

Abstract

OBJECTIVES: The principal objective of this pooled analysis was to investigate various patient and lesion characteristics on late lumen loss (LLL) after drug-coated balloon (DCB) angioplasty.
BACKGROUND: Four randomized controlled trials (THUNDER, FEMPAC, PACIFIER, CONSEQUENT) were pooled to investigate the influence of various patient and lesion characteristics on DCB angioplasty and on plain old balloon angioplasty (POBA) in patients with femoropopliteal artery disease.
METHODS: Angiographic data from 355 patients were pooled to assess the impact of patient (demographics, cardiovascular risk factors, cardiovascular co-morbidities, Rutherford stages) and lesion-/procedure-related (location, occlusion, length, restenosis, calcification, subintimal crossing, post-dilatation, dissection, stenting) characteristics on LLL. Linear regression models were utilized with LLL as the dependent variable to determine the predictive value of cardiovascular and lesion-/procedure-related factors.
RESULTS: Observational statistics revealed that LLL was lower in the DCB group as compared to POBA independent of all tested patient variables. LLL after DCB was also independent of most lesion and procedural characteristics except for lesion length and bailout stenting. LLL increased with lesion length in both treatment groups. Bailout stenting did not improve LLL in the DCB group but did so in the POBA group (0.74 ± 1.07 mm vs. 1.22 ± 1.36 mm, p = 0.043).
CONCLUSIONS: DCB was superior to POBA for all tested patient subgroups and lesion subgroups. Our results suggest that all patients and lesions benefit to a similar degree from the use of DCB. DCB-PTA should therefore be preferred to POBA in all patients with steno-occlusive femoropopliteal lesions.

Entities:  

Keywords:  Drug-coated balloon angioplasty; Femoropopliteal lesions; Late lumen loss; Pooled data analyses

Mesh:

Substances:

Year:  2018        PMID: 30539236     DOI: 10.1007/s00270-018-2137-3

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  3 in total

1.  Retrospective study of treatment with a drug-coated balloon alone is beneficial for ostial coronary lesions.

Authors:  Wenduo Zhang; Fusui Ji; Xue Yu; Chenguang Yang; Xinyue Wang
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 3.005

Review 2.  Paclitaxel-Based Devices for the Treatment of PAD: Balancing Clinical Efficacy with Possible Risk.

Authors:  Anna K Krawisz; Eric A Secemsky
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-07

3.  Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.

Authors:  John A Laird; Peter A Schneider; Michael R Jaff; Marianne Brodmann; Thomas Zeller; D Chris Metzger; Prakash Krishnan; Dierk Scheinert; Antonio Micari; Hong Wang; Michele Masters; Gunnar Tepe
Journal:  Circ Cardiovasc Interv       Date:  2019-06-14       Impact factor: 6.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.